PMGC Holdings Inc. Common Stock (ELAB)
Stock · NASDAQ · Health Care
$2.77as of 10/16/2026
Price chart
Active signals
ELAB Signal Track Record
How signals performed across all stocks →What ELAB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 12 | -8.6% | 33% | September 29, 2026 |
| Volume Spike | 10 | -44.2% | 10% | September 18, 2026 |
| Bollinger Band Breakout | 6 | -28.6% | 0% | August 20, 2026 |
| Any 20-session window (baseline) | -25.3% | 17% |
Computed by MarketWall from daily closing prices since September 9, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ELAB
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving m…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 32
- Website
- pmgcholdings.com/
Fundamentals
- 1-day range
- $3.06$3.36
- Market cap
- $4.34M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-1022.58
- Dividend yield
- —
- Beta
- -0.31
- Avg. volume
- 165.7K
PMGC Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
- REVBRevelation Biosciences Inc. Common Stock$0.485▼ 36.35%Market cap $4.38MP/E 0.04$0.71$5.8
- JUNSJupiter Neurosciences Inc. Common Stock$2.9▼ 7.48%Market cap $4.24MP/E —$2.25$135.75
- DRMADermata Therapeutics Inc. Common Stock$0.86▼ 5.49%Market cap $4.46MP/E —$0.6032$4.66
- RNAZTransCode Therapeutics Inc. Common Stock$1.7▼ 5.56%Market cap $4.52MP/E —$1.52$15.94
- JAGXJaguar Health Inc. Common Stock$3.53▼ 23.20%Market cap $4.61MP/E —$2.35$1,268
- INMInMed Pharmaceuticals Inc. Common Shares$1.32▼ 0.75%Market cap $4.01MP/E —$0.575$2.33
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
| REVB Revelation Biosciences Inc. Common Stock | $4.38M | 0.04 | $0.485 | ▼ 36.35% | $0.71$5.8 |
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $2.9 | ▼ 7.48% | $2.25$135.75 |
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $0.86 | ▼ 5.49% | $0.6032$4.66 |
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $1.7 | ▼ 5.56% | $1.52$15.94 |
| JAGX Jaguar Health Inc. Common Stock | $4.61M | — | $3.53 | ▼ 23.20% | $2.35$1,268 |
| INM InMed Pharmaceuticals Inc. Common Shares | $4.01M | — | $1.32 | ▼ 0.75% | $0.575$2.33 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Bensler Graydon · June 1, 2026 · Grant450.3K
- Parry Jeffrey · June 1, 2026 · Grant75.0K
- Kovalyov George · June 1, 2026 · Grant75.0K
- Braeden Lichti · June 1, 2026 · Grant450.3K
- Daley Juliana · June 1, 2026 · Grant75.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 64.8K
- Total value held
- $388.3K
- Institutional holders
- 6
- Unknown31.6K
- Unknown15.0K
- Unknown14.8K
- Unknown2.0K
- Unknown1.3K
- Unknown129
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
PMGC Holdings Completes $100M SPAC IPO, Launches NorthStrive
PMGC Holdings has completed a $100 million SPAC IPO, launching NorthStrive Acquisition Corp. I as the first in a planned series to expand its M&A strategy. Additionally, its subsidiary NorthStrive Biosciences has partnered with Charles River Laboratories to conduct analytical characterization for its EL-22 and EL-32 engineered probiotic programs. These moves signal a shift toward corporate expansion and advanced development partnerships for the company.
PMGC Holdings Completes $100M SPAC IPO, Launches NorthStrive. PMGC Holdings has completed a $100 million SPAC IPO, launching NorthStrive Acquisition Corp. I as the first in a planned series to expand its M&A strategy. Additionally, its subsidiary NorthStrive Biosciences has partnered with Charles River Laboratories to conduct analytical characterization for its EL-22 and EL-32 engineered probiotic programs. These moves signal a shift toward corporate expansion and advanced development partnerships for the company.